A Phase 3 interventional study of tasimelteon and Placebo in Non-24-Hour Sleep-Wake Disorder, sponsored by Vanda Pharmaceuticals. Completed at 28 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-10-16.
Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.
Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 16th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2010, is one of 10 in phase 3, and was the 20th registered.
135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.
Browse Sleep Disorders, Circadian Rhythm studies →10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 16+
Leslie Swanson · Sites in United States
Ages 18–60
Axsome Therapeutics, Inc. · Sites in United States, Canada
Ages 18–65
Yale University · Sites in United States
Ages 18+
University of Colorado, Boulder · Sites in United States
Ages 16–40 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 59 across 102 interventional studies indexed under Sleep Disorders, Circadian Rhythm.
Median enrollment 50 across the 54 interventional studies, 55 across the 15 observational. Of the 57 that completed or were terminated, 20 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 69 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 9 studies filed under Sleep Disorders, Circadian Rhythm — fewer than ten, so there is no comparison to draw.
5 of the studies in Sleep Disorders, Circadian Rhythm with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT06226025Leslie SwansonCorrecting Circadian Rhythms to Breakthrough in Bipolar Disorder | 2026-12 |
| NCT06336525Brigham and Women's HospitalAdult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities. | 2027-01-31 |
| NCT05463861Stanford UniversityLemborexant in Delayed Sleep Phase Syndrome | 2027-05-31 |
| NCT06809335Henry Ford Health SystemA Pilot of a Personalized Circadian mHealth to Improve Sleep in Night Shift Workers | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder
Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals, primarily those without light perception, are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier if \< 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping.
This will be a multicenter, randomized, double-masked, placebo-controlled, parallel study. The study has two phases: the pre-randomization phase followed by either the randomization phase or the open-label extension (OLE). The pre-randomization phase comprises a screening visit where subject's initial eligibility will be evaluated, a circadian period (τ) estimation segment, and a variable-length in-phase transition segment in which subjects will wait to start treatment until their circadian phase is aligned with their target bedtime. Subjects that meet all entry criteria for the study will enter the randomization phase. During the randomization phase, subjects will be asked to take either 20 mg tasimelteon or placebo approximately 1 hour prior to their target bedtime for 26 weeks in a double-masked fashion. Subjects who have a τ greater than 24.0 and meet all entry criteria but that are ineligible for the randomization phase due to their τ estimate may be given the opportunity to participate in the OLE phase. During the OLE phase, subjects will take open-label 20mg tasimelteon for 26 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of N24HSWD as determined by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mg tasimelteon capsules, PO daily for 6 months
Drug: tasimelteon
Placebo capsules, PO daily for 6 months
Drug: Placebo
20 mg tasimelteon capsules, PO daily for 6 months
Also known as: VEC-162
Placebo capsules, PO daily for 6 months
Proportion of Patients Entrained as Assessed by Urinary aMT6
Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four 48 hour periods , collected approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline τ value less than 24.1 and a 95% CI that included 24.0.
Time frame: 1 month
Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRS
Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score ≥ 3 on the Non-24 Clinical Response Scale (N24CRS). N24CRS measures improvement in sleep-wake measures and overall functioning (LQ-nTST, UQ-dTSD, MoST and CGI-C). Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening τ from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.
Time frame: 6 months
Proportion of Patients Entrained as Assessed by Urinary Cortisol
Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary cortisol collected over four 48 hour periods, approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline τ value less than 24.1 and a 95% CI that included 24.0.
Time frame: 1 month
Average Clinical Global Impression of Change (CGI-C)
CGI-C scores range from 1 (very much improved) to 7 (very much worse). The average post-randomization score was obtained for each patient by averaging the last 2 scheduled assessments (Day D112 and Day D183). Lower number indicates improvement.
Time frame: Day 112 and 183
Proportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 90 Minutes) and UQ-dTSD (≤ 90 Minutes)
The sleep/wake response represents measurement of the combined improvement in the nighttime sleep duration and daytime sleep duration. Individuals that have an improvement in nighttime sleep and daytime sleep, defined as an increase of 90 minutes or more in the lower quartile of subjective nighttime total sleep time (LQ-nTST) and a decrease of 90 minutes or more in the upper quartile of daytime total sleep duration (UQ-dTSD) are considered to be a responder.
Time frame: 6 months
Average Lower Quartile of Nights of Nighttime Total Sleep Time (LQ-nTST)
LQ-nTST measures the difference in average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) between the randomized phase (6 months)and the screening phase (\~ 6 weeks). The higher number indicates improvement.
Time frame: 6 months
Average Upper Quartile of Days of Subjective Daytime Sleep Duration (UQ-dTSD)
UQ-dTSD measures the difference in average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) between the randomized phase (6 months) and the screening phase (\~ 6 weeks). Lower number indicates improvement.
Time frame: 6 months
Average Midpoint of Sleep (MoST)
Midpoint of Sleep Timing (MoST) is the measurement of the average midpoint of sleep time relative to bedtime. The average MoST value will trend to 0 as an individual's sleep becomes more fragmented. Improvement is defined as an increase in the average.
Time frame: 6 months
Number of Patients With a Treatment Emergent Adverse Event (Open Label Extension Phase Only)
Adverse events were recorded in the source documents from the time of the patient's informed consent signature until the end of the patient's study participation. An AE was defined as any untoward medical occurrence in a clinical investigation patient who does not necessarily have causal relationship with treatment.
Time frame: 6 months
Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 2 on N24CRS
Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score ≥ 2 on the Non-24 Clinical Response Scale (N24CRS) which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening τ from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.
Time frame: 6 months
Proportion of Patients With a Clinical Response (Score of ≥ 3 on N24CRS)
Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline
Time frame: 6 months
Proportion of Patients With a Clinical Response (Score of ≥ 2 on N24CRS)
Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline
Time frame: 6 months
\*Various category for the Randomization Phase: 4 patients in each treatment group discontinued due to study termination by the sponsor and 1 patient in the tasimelteon group discontinued due to travel across multiple time zones
| Milestone | Tasimelteon (Randomized) | Placebo (Randomized) | Open Label Tasimelteon |
|---|---|---|---|
| Started | 42 | 42 | 0 |
| Completed | 32 | 30 | 0 |
| Not completed | 10 | 12 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 0 |
| Withdrew: Adverse event | 3 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Various* | 5 | 4 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 1 | 0 |
| Milestone | Tasimelteon (Randomized) | Placebo (Randomized) | Open Label Tasimelteon |
|---|---|---|---|
| Started | 0 | 0 | 55 |
| Completed | 0 | 0 | 39 |
| Not completed | 0 | 0 | 16 |
| Withdrew: Adverse event | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Study termination | 0 | 0 | 7 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 0 | 2 |
Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four 48 hour periods , collected approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline τ value less than 24.1 and a 95% CI that included 24.0.
| percentage of patients | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Proportion of Patients Entrained as Assessed by Urinary aMT6 | 20 | 2.6 |
Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score ≥ 3 on the Non-24 Clinical Response Scale (N24CRS). N24CRS measures improvement in sleep-wake measures and overall functioning (LQ-nTST, UQ-dTSD, MoST and CGI-C). Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening τ from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.
| percentage of patients | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRS | 23.7 | 0 |
Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score ≥ 2 on the Non-24 Clinical Response Scale (N24CRS) which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening τ from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.
| percentage of patients | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 2 on N24CRS | 28.9 | 0 |
Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline
| percentage of patients | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Proportion of Patients With a Clinical Response (Score of ≥ 3 on N24CRS) | 28.9 | 2.9 |
Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary cortisol collected over four 48 hour periods, approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline τ value less than 24.1 and a 95% CI that included 24.0.
| percentage of patients | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Proportion of Patients Entrained as Assessed by Urinary Cortisol | 17.5 | 2.6 |
CGI-C scores range from 1 (very much improved) to 7 (very much worse). The average post-randomization score was obtained for each patient by averaging the last 2 scheduled assessments (Day D112 and Day D183). Lower number indicates improvement.
| score | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Average Clinical Global Impression of Change (CGI-C) | 2.6 ± 0.20 | 3.4 ± 0.21 |
The sleep/wake response represents measurement of the combined improvement in the nighttime sleep duration and daytime sleep duration. Individuals that have an improvement in nighttime sleep and daytime sleep, defined as an increase of 90 minutes or more in the lower quartile of subjective nighttime total sleep time (LQ-nTST) and a decrease of 90 minutes or more in the upper quartile of daytime total sleep duration (UQ-dTSD) are considered to be a responder.
| percentage of patients | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Proportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 90 Minutes) and UQ-dTSD (≤ 90 Minutes) | 13.2 | 2.9 |
LQ-nTST measures the difference in average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) between the randomized phase (6 months)and the screening phase (\~ 6 weeks). The higher number indicates improvement.
| minutes | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Average Lower Quartile of Nights of Nighttime Total Sleep Time (LQ-nTST) | 56.80 ± 9.305 | 17.08 ± 9.702 |
UQ-dTSD measures the difference in average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) between the randomized phase (6 months) and the screening phase (\~ 6 weeks). Lower number indicates improvement.
| minutes | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Average Upper Quartile of Days of Subjective Daytime Sleep Duration (UQ-dTSD) | -46.48 ± 6.595 | -17.87 ± 6.889 |
Midpoint of Sleep Timing (MoST) is the measurement of the average midpoint of sleep time relative to bedtime. The average MoST value will trend to 0 as an individual's sleep becomes more fragmented. Improvement is defined as an increase in the average.
| minutes | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Average Midpoint of Sleep (MoST) | 35.00 ± 5.313 | 14.48 ± 5.547 |
Responder analysis with responder defined as an increase of 45 minutes or more in (LQ-nTST) and a decrease of 45 minutes or more in (UQ-dTSD).
| percentage of patients | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Proportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 45 Minutes) and UQ-dTSD (≤ 45 Minutes) | 31.6 | 8.8 |
Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline
| percentage of patients | Tasimelteon (Randomized) | Placebo (Randomized) |
|---|---|---|
| Proportion of Patients With a Clinical Response (Score of ≥ 2 on N24CRS) | 57.9 | 20.6 |
Adverse events were recorded in the source documents from the time of the patient's informed consent signature until the end of the patient's study participation. An AE was defined as any untoward medical occurrence in a clinical investigation patient who does not necessarily have causal relationship with treatment.
| participants | Open Label Tasimelteon |
|---|---|
| Number of Patients With a Treatment Emergent Adverse Event (Open Label Extension Phase Only) | 37 |
Collected over 1st dose to 30 days following last administration of study treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tasimelteon (Randomized) | — | 4/42 (9.5%) | 20/42 (47.6%) |
| Placebo (Randomized) | — | 2/42 (4.8%) | 13/42 (31%) |
| Open Label Tasimelteon | — | 2/54 (3.7%) | 21/54 (38.9%) |
| Event | Tasimelteon (Randomized) | Placebo (Randomized) | Open Label Tasimelteon |
|---|---|---|---|
| Procedural PainInjury, poisoning and procedural complications | 0/42 | 1/42 | 0/54 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/42 | 1/42 | 0/54 |
| SyncopeNervous system disorders | 1/42 | 0/42 | 0/54 |
| Acute Lymphocytic LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/42 | 0/42 | 0/54 |
| CholecystitisHepatobiliary disorders | 1/42 | 0/42 | 0/54 |
| DiverticulitisInfections and infestations | 1/42 | 0/42 | 0/54 |
| Serotonin SyndromeNervous system disorders | 0/42 | 0/42 | 1/54 |
| Transient Ischaemic AttackNervous system disorders | 0/42 | 0/42 | 1/54 |
| Event | Tasimelteon (Randomized) | Placebo (Randomized) | Open Label Tasimelteon |
|---|---|---|---|
| HeadacheNervous system disorders | 7/42 | 3/42 | 4/54 |
| NasopharyngitisInfections and infestations | 3/42 | 4/42 | 5/54 |
| Alanine aminotransferase increasedInvestigations | 4/42 | 2/42 | 2/54 |
| Urinary tract infectionInfections and infestations | 3/42 | 1/42 | 5/54 |
| NauseaGastrointestinal disorders | 1/42 | 3/42 | 0/54 |
| Asparate aminotransferase increasedInvestigations | 3/42 | 2/42 | 3/54 |
| Oedema peripheralGeneral disorders | 3/42 | 2/42 | 0/54 |
| Upper respiratory tract infectionInfections and infestations | 3/42 | 0/42 | 2/54 |
| Gamma-glutamyltransferase increasedInvestigations | 0/42 | 2/42 | 3/54 |
| Abnormal dreamsPsychiatric disorders | 2/42 | 0/42 | 3/54 |
52 patients entered the OLE Phase from screening and 3 patients rolled over after completing the Randomization Phase (2:tasimelteon; 1:placebo). For this analysis, 3 patients are included in the randomized arms and not the OLE. A separate analysis has been done for both age and gender for the 3 subjects (Rand to OLE).
| Age, Continuous(years) | Tasimelteon (Randomized) | Placebo (Randomized) | Open Label Tasimelteon | Total |
|---|---|---|---|---|
| Mean | 50.8 ± 12.63 | 50.7 ± 13.15 | 50.37 ± 13.17 | 50.6 ± 12.91 |
| Age, Customized(years) | Tasimelteon (Randomized) | Placebo (Randomized) | Open Label Tasimelteon | Total |
|---|---|---|---|---|
| Rand to OLE | 42.00 ± 5.66 | 54.00 ± NA | NA ± NA | 46.00 ± 8.00 |
| Sex/Gender, Customized(participants) | Tasimelteon (Randomized) | Placebo (Randomized) | Open Label Tasimelteon | Total |
|---|---|---|---|---|
| Rand to OLE (Female) | 0 | 0 | 0 | 0 |
| Rand to OLE (Male) | 2 | 1 | 0 | 3 |
| Sex: Female, Male(Participants) | Tasimelteon (Randomized) | Placebo (Randomized) | Open Label Tasimelteon | Total |
|---|---|---|---|---|
| Female | 18 | 17 | 25 | 60 |
| Male | 24 | 25 | 27 | 76 |
The record gives a start of Aug 2010, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 11 months after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon
Sleep Disorders, Circadian Rhythm →